HD21 for Advanced Stages


Primary objective of the trial is to demonstrate non-inferior efficacy of six cycles of BrECADD compared to six cycles of escalated BEACOPP, each followed by radiotherapy to PET-positive residual lesions ≥2.5 cm, in terms of progression free survival (efficacy objective).

If non-inferior efficacy can be shown, the co-primary objective is to further demonstrate reduced toxicity of the BrECADD treatment compared to the escalated BEACOPP treatment measured by treatment related morbidity (TRMorbidity objective).

Full Title of Study: “HD21 for Advanced Stages Treatment Optimization Trial in the First-line Treatment of Advanced Stage Hodgkin Lymphoma; Comparison of 6 Cycles of Escalated BEACOPP With 6 Cycles of BrECADD”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2020


  • Drug: Bleomycin
  • Drug: Etoposide
  • Drug: Doxorubicin
  • Drug: Cyclophosphamide
  • Drug: Vincristine
  • Drug: Procarbazine
  • Drug: Prednisone
  • Drug: Brentuximab Vedotin
  • Drug: Dacarbazine
  • Drug: Dexamethasone

Arms, Groups and Cohorts

  • Active Comparator: BEACOPP
    • 4 or 6 cycles of BEACOPP (21-day cycles) Bleomycin (B) Etoposide (E) Doxorubicin (A) Cyclophosphamide (C) Vincristine (O) Procarbazin (P) Prednisone (P). If FDG-PET is negative after two cycles patients will be given a total of four cycles. If FDG-PET is positive after two cycles patients will bev given a total of six cycles.
  • Experimental: BRECADD
    • 4 or 6 cycles of BRECADD (21.day cycles) Brentuximab Vedotin (BR) Etoposide (E) Cyclophosphamide (C) Doxorubicin (A) Dacarbazine (D) Dexamethasone (D). If FDG-PET is negative after two cycles patients will be given a total of four cycles. If FDG-PET is positive after two cycles patients will be given a total of six cycles.

Clinical Trial Outcome Measures

Primary Measures

  • Progression Free Survival
    • Time Frame: 5 years
  • Treatment Related Morbidity
    • Time Frame: during 6 cycles of chemotherapy (21-day cycles)

Participating in This Clinical Trial

Inclusion Criteria

  • Histologically proven classical Hodgkin lymphoma
  • First diagnosis, no previous treatment, 18 to 60 years of age
  • Stage IIB with large mediastinal mass and/or extranodal lesions, stage III or IV

Exclusion Criteria

  • Composite lymphoma or nodular lymphocyte-predominant Hodgkin lymphoma
  • Previous malignancy (exceptions: basalioma, carcinoma in situ of the cervix uteri, completely resected melanoma TNMpT1)
  • Prior chemotherapy or radiotherapy

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Cologne
  • Provider of Information About this Clinical Study
    • Principal Investigator: Prof. Dr. Peter Borchmann, Prof. – University of Cologne
  • Overall Official(s)
    • Peter Borchmann, Prof., Principal Investigator, University of Cologne, I. Dept. of Medicine
  • Overall Contact(s)
    • Michael Fuchs, ghsg@uk-koeln.de

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.